PLATFORM TECHNOLOGY. It is the expectation of the Parties that Amgen will not share with or disclose to RBNC any Amgen Platform Technology and RBNC will not share with or disclose to Amgen any RBNC Platform Technology. In the event the Parties agree to disclose any Amgen Platform Technology and/or any RBNC Platform Technology in connection with the performance of the Collaboration Activities, or incorporate any Amgen Platform Technology and/or any RBNC Platform Technology into the Collaboration Activities, the Parties will discuss in good faith and agree in writing to protections and processes to ensure: (a) Amgen retains and shall be the exclusive owner of all right, title and interest in and to any and all inventions to the extent such inventions are modifications of or improvements to the Amgen Platform Technology that are invented or generated in the course of either Party performing Collaboration Activities. (b) RBNC retains and shall be the exclusive owner of all right, title and interest in and to any and all inventions to the extent such inventions are modifications of or improvements to the RBNC Platform Technology that are invented or generated in the course of either Party performing Collaboration Activities.
Appears in 2 contracts
Sources: Research Collaboration and License Agreement (Neumora Therapeutics, Inc.), Research Collaboration and License Agreement (Neumora Therapeutics, Inc.)